NYSE: $PFE
NEW YORK–(BUSINESS WIRE) October 01, 2026 — Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis (AD). The study met its…
Source: Read More